Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
11.98
USD
|
-2.68%
|
|
-0.99%
|
+75.66%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,242
|
2,006
|
707.5
|
213.1
|
297.5
|
525.7
|
-
|
-
|
Enterprise Value (EV)
1 |
1,242
|
1,891
|
525.9
|
107.3
|
219.8
|
417.8
|
398.3
|
367.5
|
P/E ratio
|
-13.6
x
|
-16.7
x
|
-12.7
x
|
-2.23
x
|
-13.9
x
|
-22.9
x
|
-23.4
x
|
-10.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
96.7
x
|
20.3
x
|
3.27
x
|
3.51
x
|
5.44
x
|
4.48
x
|
4.2
x
|
EV / Revenue
|
-
|
91.1
x
|
15.1
x
|
1.64
x
|
2.59
x
|
4.32
x
|
3.4
x
|
2.93
x
|
EV / EBITDA
|
-15
x
|
-15.8
x
|
-4.59
x
|
-1.14
x
|
-8.81
x
|
-19.1
x
|
-35.3
x
|
-112
x
|
EV / FCF
|
-16.5
x
|
-20.7
x
|
-5.09
x
|
-1.41
x
|
-
|
-12.7
x
|
-12.8
x
|
-
|
FCF Yield
|
-6.08%
|
-4.83%
|
-19.6%
|
-70.7%
|
-
|
-7.9%
|
-7.78%
|
-
|
Price to Book
|
6.24
x
|
18.8
x
|
3.89
x
|
1.95
x
|
2.95
x
|
9.98
x
|
8.5
x
|
6.89
x
|
Nbr of stocks (in thousands)
|
39,728
|
40,514
|
43,644
|
43,668
|
43,622
|
43,883
|
-
|
-
|
Reference price
2 |
31.25
|
49.51
|
16.21
|
4.880
|
6.820
|
11.98
|
11.98
|
11.98
|
Announcement Date
|
3/12/20
|
2/25/21
|
2/24/22
|
3/30/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
20.75
|
34.9
|
65.27
|
84.82
|
96.7
|
117.2
|
125.3
|
EBITDA
1 |
-82.84
|
-119.5
|
-114.7
|
-93.97
|
-24.94
|
-21.89
|
-11.29
|
-3.282
|
EBIT
1 |
-83
|
-119.9
|
-115.4
|
-94.81
|
-25.67
|
-22.94
|
-19.21
|
-46.21
|
Operating Margin
|
-
|
-578%
|
-330.78%
|
-145.27%
|
-30.27%
|
-23.72%
|
-16.39%
|
-36.89%
|
Earnings before Tax (EBT)
1 |
-81.03
|
-119.3
|
-55.28
|
-95.57
|
-20.87
|
-25.39
|
-31.9
|
-66.45
|
Net income
1 |
-81.03
|
-119.3
|
-55.28
|
-95.57
|
-21.43
|
-23.58
|
-26.18
|
-66.45
|
Net margin
|
-
|
-575.12%
|
-158.39%
|
-146.43%
|
-25.26%
|
-24.38%
|
-22.33%
|
-53.05%
|
EPS
2 |
-2.300
|
-2.970
|
-1.280
|
-2.190
|
-0.4900
|
-0.5225
|
-0.5125
|
-1.120
|
Free Cash Flow
1 |
-75.46
|
-91.41
|
-103.2
|
-75.92
|
-
|
-33
|
-31
|
-
|
FCF margin
|
-
|
-440.51%
|
-295.79%
|
-116.32%
|
-
|
-34.13%
|
-26.44%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
2/25/21
|
2/24/22
|
3/30/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
9.598
|
10.49
|
10.8
|
12.54
|
31.45
|
20.25
|
20.75
|
20.45
|
23.36
|
19.93
|
23.43
|
25.6
|
27.63
|
26.21
|
29.48
|
EBITDA
|
-35.47
|
-27.5
|
-39.76
|
-25.79
|
-0.923
|
-7.319
|
-6.999
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-35.76
|
-27.7
|
-39.94
|
-26.02
|
-1.153
|
-7.501
|
-7.223
|
-7.749
|
-3.199
|
-6.908
|
-6.509
|
-6.272
|
-6.84
|
-2.236
|
-2.626
|
Operating Margin
|
-372.56%
|
-264.11%
|
-369.96%
|
-207.52%
|
-3.67%
|
-37.04%
|
-34.81%
|
-37.89%
|
-13.69%
|
-34.66%
|
-27.78%
|
-24.5%
|
-24.75%
|
-8.53%
|
-8.91%
|
Earnings before Tax (EBT)
1 |
-36.89
|
-28.07
|
-41.13
|
-27.53
|
1.157
|
-6.39
|
-6.123
|
-7.56
|
-0.793
|
-6.469
|
-6.326
|
-6.063
|
-6.52
|
-2.026
|
-2.392
|
Net income
1 |
-36.89
|
-28.07
|
-41.13
|
-27.53
|
1.157
|
-6.39
|
-6.302
|
-7.747
|
-0.988
|
-6.629
|
-6.326
|
-6.063
|
-6.52
|
-2.026
|
-2.392
|
Net margin
|
-384.38%
|
-267.67%
|
-380.95%
|
-219.56%
|
3.68%
|
-31.55%
|
-30.37%
|
-37.88%
|
-4.23%
|
-33.26%
|
-27%
|
-23.68%
|
-23.59%
|
-7.73%
|
-8.11%
|
EPS
2 |
-0.8500
|
-0.6400
|
-0.9400
|
-0.6300
|
0.0300
|
-0.1500
|
-0.1400
|
-0.1800
|
-0.0200
|
-0.1500
|
-0.1575
|
-0.1425
|
-0.1500
|
-0.1300
|
-0.1250
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/9/22
|
8/8/22
|
11/7/22
|
3/30/23
|
5/8/23
|
8/10/23
|
11/13/23
|
2/29/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
115
|
182
|
106
|
77.7
|
108
|
127
|
158
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-75.5
|
-91.4
|
-103
|
-75.9
|
-
|
-33
|
-31
|
-
|
ROE (net income / shareholders' equity)
|
-47.7%
|
-78.3%
|
-38.7%
|
-66.1%
|
-20.4%
|
-17.6%
|
-5.94%
|
0.72%
|
ROA (Net income/ Total Assets)
|
-44%
|
-68.5%
|
-32.1%
|
-54%
|
-
|
-
|
-
|
-
|
Assets
1 |
184.1
|
174.2
|
172.4
|
177.1
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
5.010
|
2.640
|
4.170
|
2.500
|
2.310
|
1.200
|
1.410
|
1.740
|
Cash Flow per Share
2 |
-2.090
|
-2.270
|
-2.370
|
-1.740
|
-0.6200
|
-0.1500
|
-0.0300
|
-
|
Capex
1 |
1.97
|
0.18
|
0.67
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
0.84%
|
1.91%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
2/25/21
|
2/24/22
|
3/30/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
11.98
USD Average target price
21.33
USD Spread / Average Target +78.07% Consensus |
1st Jan change
|
Capi.
|
---|
| +75.66% | 526M | | +18.72% | 125B | | +14.19% | 108B | | -4.93% | 24.21B | | +0.82% | 22.78B | | -10.79% | 17.96B | | -41.74% | 16.43B | | -13.31% | 16.37B | | +2.44% | 13.58B | | +27.89% | 11.66B |
Bio Therapeutic Drugs
|